Supernus Pharmaceuticals, Inc. notified Nasdaq of the completion of its merger on November 2, 2026, and requested the suspension and delisting of its common stock. The company intends to deregister its shares and suspend its reporting obligations under the Exchange Act as it will no longer be listed on any national securities exchange.
Supernus Pharmaceuticals M&A Deal with Indivior Pharmaceuticals, Inc.
Supernus Pharmaceuticals completed its previously announced merger with Indivior Pharmaceuticals, with Supernus becoming a wholly owned subsidiary of the combined entity, which has been renamed Supernus, Inc. Supernus stockholders received 1.5401 shares of the combined company for each share held, and the transaction was supported by a new $650 million senior secured term loan facility.
Supernus Pharmaceuticals M&A Deal with Indivior Pharmaceuticals Inc.
Supernus Pharmaceuticals stockholders approved the company's acquisition by Indivior Pharmaceuticals at a special meeting held on October 15, 2026. Under the terms of the merger agreement, Supernus will become a wholly-owned subsidiary of Indivior. Stockholders also approved, on a non-binding basis, the merger-related compensation for the company's named executive officers.